Trail­ing No­var­tis and Eli Lil­ly, ra­dio­phar­ma­ceu­ti­cals start­up Full-Life Tech­nolo­gies nabs $63M to test new PS­MA drug

As the US ra­dio­phar­ma­ceu­ti­cal space heats up with the ac­qui­si­tions of Rayze­Bio and Point Bio­phar­ma, a younger start­up based out of Chi­na and Bel­gium has raised $63.3 mil­lion to put its first pro­gram in the clin­ic.

Full-Life Tech­nolo­gies’ lat­est fi­nanc­ing is made up of a $47.3 mil­lion Se­ries B co-led by Pros­per­i­ty7 Ven­tures and an undis­closed health­care spe­cial­ist in­vestor, and a $16 mil­lion bank loan.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER